Quantbot Technologies LP Acquires Shares of 28,210 Teleflex Incorporated (NYSE:TFX)

Quantbot Technologies LP bought a new stake in Teleflex Incorporated (NYSE:TFX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 28,210 shares of the medical technology company's stock, valued at approximately $5,021,000. Quantbot Technologies LP owned approximately 0.06% of Teleflex as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Apollon Wealth Management LLC increased its position in shares of Teleflex by 3.7% during the third quarter. Apollon Wealth Management LLC now owns 1,524 shares of the medical technology company's stock valued at $377,000 after acquiring an additional 55 shares during the last quarter. SRS Capital Advisors Inc. lifted its position in shares of Teleflex by 0.3% during the third quarter. SRS Capital Advisors Inc. now owns 19,587 shares of the medical technology company's stock worth $4,844,000 after purchasing an additional 60 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. boosted its position in Teleflex by 4.5% in the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 1,517 shares of the medical technology company's stock valued at $375,000 after buying an additional 66 shares during the period. HighTower Advisors LLC boosted its holdings in Teleflex by 1.7% in the third quarter. HighTower Advisors LLC now owns 3,998 shares of the medical technology company's stock valued at $986,000 after purchasing an additional 66 shares during the period. Finally, Huntington National Bank grew its stake in Teleflex by 32.5% during the 3rd quarter. Huntington National Bank now owns 310 shares of the medical technology company's stock worth $77,000 after purchasing an additional 76 shares in the last quarter. 95.62% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Teleflex Stock Performance

Shares of TFX traded down $1.01 during midday trading on Wednesday, reaching $138.95. 1,172,792 shares of the stock were exchanged, compared to its average volume of 499,590. Teleflex Incorporated has a twelve month low of $128.55 and a twelve month high of $249.91. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.42 and a quick ratio of 1.39. The company has a market capitalization of $6.44 billion, a price-to-earnings ratio of 27.62, a PEG ratio of 1.73 and a beta of 1.21. The business's 50-day moving average price is $165.38 and its 200 day moving average price is $195.90.

Teleflex (NYSE:TFX - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The medical technology company reported $3.89 EPS for the quarter, topping the consensus estimate of $3.86 by $0.03. The company had revenue of $795.40 million for the quarter, compared to analyst estimates of $813.24 million. Teleflex had a return on equity of 14.19% and a net margin of 7.85%. On average, sell-side analysts expect that Teleflex Incorporated will post 13.98 EPS for the current fiscal year.

Teleflex Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, March 17th. Investors of record on Friday, March 7th were paid a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 0.98%. The ex-dividend date of this dividend was Friday, March 7th. Teleflex's dividend payout ratio is currently 95.77%.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Morgan Stanley decreased their price objective on Teleflex from $275.00 to $191.00 and set an "overweight" rating for the company in a research note on Wednesday, March 5th. Bank of America cut shares of Teleflex from a "neutral" rating to an "underperform" rating and lowered their price target for the stock from $235.00 to $140.00 in a report on Tuesday, March 4th. Truist Financial reduced their price objective on shares of Teleflex from $200.00 to $149.00 and set a "hold" rating on the stock in a report on Monday, March 3rd. Citizens Jmp downgraded shares of Teleflex from an "outperform" rating to a "market perform" rating in a research note on Thursday, February 27th. Finally, Needham & Company LLC restated a "hold" rating on shares of Teleflex in a research note on Wednesday, March 12th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat, Teleflex presently has an average rating of "Hold" and an average price target of $182.63.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.